XAIR Stock Forecast & Price Target

Beyond Air Inc. demonstrated a strong financial performance with a 157% increase in revenue, reaching $1.8 million for the quarter ended June 30, 2025, bolstered by the robust demand for its LungFit PH system. The company achieved a significant shift in its growth trajectory, as evidenced by a positive gross profit of $0.2 million compared to a gross loss of $0.3 million in the prior year. Additionally, the establishment of a national group purchasing agreement with Premier, Inc. enhances access for its innovative nitric oxide delivery system, paving the way for further commercial growth and technology adoption in both domestic and international markets.

Beyond Air Inc. reported a reduced gross loss of $0.3 million compared to $1.1 million from the previous year, however, the company still experienced a significant net loss of $7.9 million, or $1.25 per share, emphasizing ongoing financial struggles. Despite decreases in research and development (R&D) expenses to $2.5 million and selling, general and administrative (SG&A) expenses to $4.9 million, the net cash burn amounting to $4.7 million raises concerns about the firm's financial sustainability. The company faces fundamental challenges tied to its product's potential adverse effects, including disruptions in cellular respiration and induced stress in tumor environments, which could hinder its market viability and overall growth prospects.